Li Kai.Current status and recent advances in drug therapies of Kaposiform hemangioendothelioma[J].Journal of Clinical Pediatric Surgery,2019,18(08):626-628.[doi:10.3969/j.issn.1671-6353.2019.08.002]
卡波西样血管内皮瘤的药物治疗现状和进展
- Title:
- Current status and recent advances in drug therapies of Kaposiform hemangioendothelioma
- Keywords:
- Hemangioendothelioma/TH; Drug Therapy
- 分类号:
- R543;R732.2;R91
- 摘要:
- 卡波西样血管内皮瘤（kaposiform hemagioendothelioma，KHE）是一种少见的主要发生于婴幼儿和儿童的真性血管性肿瘤，往往呈现局灶性进展，一般不发生远处转移，累及部位主要有头颈部、躯干和四肢，可累及一个或多个部位。与婴儿血管瘤不同，目前国内尚没有针对卡波西样血管内皮瘤的标准化治疗方案，国内外也没有明确的治疗指南。因此，本文就卡波西样血管内皮瘤的诊断、药物治疗共识的现状及新进展进行简要的回顾和总结，希望通过多中心大样本前瞻性研究来制定卡波西样血管内皮瘤药物治疗的指证、指南及共识。
- Abstract:
- As a rare true angioma occurring predominantly in infants and toddlers,Kaposiform hemangioendothelioma (KH) is often manifested as local progression without a distant metastasis.One or multiple sites,including head,neck,torso and extremities,may be involved.Different from angioma,currently there is no domestic standard protocol for its treatments.And a definite international guideline is also lacking.Thus this paper was intended for reviewing and summarizing the diagnostic and therapeutic consensus of KH.Hopefully multi-center large-sample prospective trials are conducted for formulating the indications,guidelines and consensus of drug treatments for KH.
参考文献/References:
1 孙玉环,车宗刚,郑家伟.ISSVA2018脉管异常新分类[J].中国口腔颌面外科杂志,2019,17(1):7-13.DOI:10.19438/j.cjoms.2019.01.003.Sun YH,Che ZG,Zheng JW.2018 newly revised ISSVA classification for vascular anomalies[J].China Journal of Oral & Maxillofacial Surgery,2019,17(1):7-13.DOI:10.19438/j.cjoms.2019.01.003.
2 Sarkar M,Mulliken JB,Kozakewich HP,et al.Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma[J].Plast Reconstr Surg,1997,100(6):1377-1386.
3 Chinello M,Di Carlo D,Olivieri F,et al.Successful management of Kaposiform hemangioendothelioma with long-term sirolimustreatment:a case report and review of the literature[J].Mediterr J Hematol Infect Dis,2018,10(1):e2018043.
4 Mazoyer E,Enjolras O,Laurian C,et al.Coagulation abnormalities associated with extensive venous malformations of the limbs:differentiation from Kasabach-Merritt syndrome[J].Clin Lab Haematol,2002,24(4):243-251.DOI:10.1046/j.1365-2257.2002.00447.x.
5 Kim T,Roh MR,Cho S,et al.Kasabach-merritt syndrome arising from tufted angioma successfully treated with systemic corticosteroid[J].Ann Dermatol,2010,22(4):426-430.DOI:10.5021/ad.2010.22.4.426.
6 Haisley-Royster C,Enjolras O,Frieden IJ,et al.Kasabach-merritt phenomenon:a retrospective study of treatment with vincristine[J].J PediatrHematol Oncol,2002,24(6):459-462.
7 Wang Z,Li K,Yao W,et al.Steroid-resistant kaposiform hemangioendothelioma:a retrospective study of 37 patients treated with vincristine and long-term follow-up[J].Pediatr Blood Cancer,2015,62(4):577-580.DOI:10.1002/pbc.25296.
8 Acharya S,Pillai K,Francis A,et al.Kasabachmerritt syndrome:management with interferon[J].Indian J Dermatol,2010,55(3):281-283.DOI:10.4103/0019-5154.70705.
9 Drolet B,Trenor CC,Brandão LR,et al.Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma[J].J Pediatr,2013,163(1):285-291.DOI:10.1016/j.jpeds.2013.03.080.
10 Hammill AM,Wentzel M,Gupta A,et al.Sirolimus for the treatment of complicated vascular anomalies in children[J].Pediatr Blood Cancer,2011,57(6):1018-1024.DOI:10.1002/pbc.23124.
11 Kai L,Wang Z,Yao W,et al.Sirolimus,a promising treatment for refractory Kaposiform hemangioendothelioma[J].J Cancer Res Clin Oncol,2014,140(3):471-476.DOI:10.1007/s00432-013-1549-3.
12 O’rafferty C,O’regan GM,Irvine AD,et al.Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon[J].Br J Haematol,2015,171(1):38-51.DOI:10.1111/bjh.13557.
13 Yao W,Li K,Wang Z,et al.Comparison of corticosteroid and vincristine in treating kaposiform hemangioendothelioma and tufted angioma:a systematic review and meta-analysis[J].Eur J Pediatr Surg,2018.DOI:10.1055/s-0038-1673708.
14 Schmid I,Klenk AK,Sparber-Sauer M,et al.Kaposiformhemangioendothelioma in children:a benign vascular tumor with multiple treatment options[J].World J Pediatr,2018,14(4):322-329.DOI:10.1007/s12519-018-0171-5.
15 Ji Y,Yang K,Chen S,et al.Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon:clinical characteristics and management[J].Cancer Manag Res,2018,10:3325-3331.DOI:10.2147/CMAR.S171223.
相似文献/References:
[1]丁颖菁,李凯.西罗莫司在小儿卡波西型血管内皮瘤中的应用进展[J].临床小儿外科杂志,2022,21(10):987.[doi:10.3760/cma.j.cn101785-202008017-015]
Ding Yingjing,Li Kai.Current applications and future perspectives of sirolimus in the treatment of kaposiform hemangioendothelioma[J].Journal of Clinical Pediatric Surgery,2022,21(08):987.[doi:10.3760/cma.j.cn101785-202008017-015]
[2]杨屹,刘鑫.儿童膀胱/前列腺横纹肌肉瘤治疗进展[J].临床小儿外科杂志,2022,21(12):1101.[doi:10.3760/cma.j.cn101785-202206005-001]
Yang Yi,Liu Xin.Recent advances in the treatment of bladder/prostate rhabdomyosarcoma in children[J].Journal of Clinical Pediatric Surgery,2022,21(08):1101.[doi:10.3760/cma.j.cn101785-202206005-001]
[3]张晔,张殷,蒋加斌,等.小剂量索利那新治疗儿童特发性膀胱过度活动症的短期疗效与安全性分析[J].临床小儿外科杂志,2023,22(02):134.[doi:10.3760/cma.j.cn101785-202210053-007]
Zhang Ye,Zhang Yin,Jiang Jiabin,et al.Short-term efficacy and safety of low-dose solifenacin for newly diagnosed idiopathic overactive bladder in children[J].Journal of Clinical Pediatric Surgery,2023,22(08):134.[doi:10.3760/cma.j.cn101785-202210053-007]
备注/Memo
收稿日期:2019-04-15。
基金项目:上海市卫生系统优秀人才培养计划（编号：2017BR052）